CD19 and lymphoma: To deliver CARs via a lentivirus (LV) to patients with relapsed or resistant CD19+ lymphoma and leukemia, gene-disrupted allogeneic universal CD19-specific CAR-T cells (UCART019) were used in a different trial [174].